Every spring, CMS publishes a document almost nobody outside a health-insurance actuarial department reads: the Medicare Advantage rate notice. It sets the per-member payment insurers get for every senior enrolled in a private Medicare plan, and it recalibrates the risk-adjustment model that decides how much extra insurers get paid for "sicker" patients. For CY2027, CMS finalized a 2.48% base rate increase — roughly $13 billion in new payments to MA plans — and, critically, chose to keep using the older 2024 risk-adjustment model rather than the tighter recalibration it had floated. On top of that, CMS runs a quality bonus program that pays roughly $13 billion a year in "star rating" bonuses to plans that hit 4 stars or higher. That single regulatory lever — not admissions, not procedure volume — is what actually moves earnings at the biggest Medicare Advantage franchises.
Why UNH Is Really a Policy Stock, Not a Health Insurer
CMS rate notices and star-rating bonuses swing UnitedHealth's earnings more than any hospital admission ever will — and the same mechanism is now a two-way street for the whole Medicare Advantage complex.
| Ticker | Company | 1-year change |
|---|---|---|
| UNH | UnitedHealth | +20.3% |
CMS didn't cut a single hospital's reimbursement this year — it just decided which risk-adjustment model to keep, and that one line item is worth billions more to UNH than every ER visit in America combined.
Who cashes in
UnitedHealth UNH is the biggest beneficiary of both mechanisms at once. It covers roughly a quarter of all MA enrollees but is projected to capture about 29% of 2026 quality-bonus dollars — call it $3.9 billion — because Optum's scale lets it manage star ratings and risk-adjustment coding more aggressively than any peer, and a favorable court ruling forced CMS to recalculate UnitedHealthcare's 2025 stars in its favor.
Humana HUM lives or dies by the same star-bonus formula even more directly than UNH, since MA is nearly its entire business; a rate notice that holds risk-adjustment steady rather than cutting it is pure operating-leverage upside for Humana's plan margins.
Elevance ELV and Centene CNC don't benefit from MA rates the same way, but both are geared to the Medicaid side of the same CMS rulemaking apparatus — federal matching-rate and redetermination policy, not hospital utilization, is what's setting their 2026 guidance.
Who is exposed
Elevance ELV is guiding to roughly -1.75% Medicaid margins in 2026, a swing driven almost entirely by state redetermination policy pushing lower-acuity members off the rolls and leaving a sicker, costlier risk pool — a policy-driven headwind, not a claims-cost surprise. Centene CNC is near-breakeven in Medicaid for the same reason, concentrated in Florida and Texas redetermination churn. CVS CVS carries PBM/Caremark exposure to the FTC's insulin-pricing settlement and pending Consolidated Appropriations Act spread-pricing reforms that could compress Optum-style captive-PBM economics across the sector, CVS included.
The play: Track the CMS rate notice and star-ratings fact sheet like an earnings release — they move MA-exposed names before any 10-Q does. Watch HUM and UNH stars data each October; watch state Medicaid redetermination completion rates for ELV/CNC's 2027 setup.
What to watch: the CY2028 Advance Notice (expected February), and whether Congress revisits PBM spread-pricing reform this session.
Source: original report ↗
Free: catalyst alerts, straight to your inbox.
Get the White House orders, federal contracts, and FDA decisions that move money — with who cashes in — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Money Racket Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $40/moJoin the owners who run ahead of the industry. Cancel anytime, one click.